ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

On-and-off fasting helps fight obesity, study finds

16 Tips from 16 Years Sick

Fibromyalgia Fare Fit for All Seasons

New Study Shows Artificial Sweeteners Lead to Diabetes

Essential Oils — An Effective and Healthy Option to Treat Headaches

Higher vitamin D levels associated with less severe disease in NAFLD patients

Can Pomegranates Slow Aging?

Krill Oil: Make This Omega-3 Supplement Part of Your Health Regimen

How zinc helps fight esophageal cancer

What Benefits Can You Get From High-Quality Whey Protein?

Print Page
Email Article

Neuroprotective Therapies for Parkinson's Disease

  [ 59 votes ]   [ Discuss This Article ] • January 22, 2004

Source: From Medscape Pharmacists

Conference Report

Neuroprotection in Parkinson's Disease

American College of Clinical Pharmacy Annual Meeting; November 2-5, 2003; Atlanta, Georgia

Posted 01/20/2004

Jack J. Chen, PharmD, BCPS, CGP
The currently available therapies for PD are symptomatic and become less effective over time due to progression of the underlying disease process. Therefore, a crucial need for therapies that slow or arrest disease progression has been identified. It is important to note that experts within the area of neuroprotection agree that all human neuroprotective studies to date are characterized by study design and technical methodology limitations that prevent definitive statements of successful neuroprotection and that the design of future neuroprotective trials is a complex process.

Nevertheless, in order to identify potential neuroprotective agents available for testing, the Committee to Identify Neuroprotective Agents in Parkinson's (CINAPS), supported by the National Institute of Neurologic Disorders and Stroke (NINDS), conducted a systematic assessment of currently available pharmacologic agents. From a list of 59 potential neuroprotective agents, the Committee identified 12 agents that are currently available and should be considered priority agents for further investigation in PD (Table).


Several epidemiologic studies have demonstrated that high intake of caffeine (ie, coffee, tea) is associated with an inverse risk of developing PD, and animal experiments support protective effects of caffeine. Caffeine is an adenosine receptor antagonist, and the compound KW-6002, a specific adenosine 2A receptor antagonist, has demonstrated neuroprotective effects in animal models of PD.

Coenzyme Q10

Also referred to as "CoQ10," this compound is a dietary supplement that is widely available. In a recent phase 2 study, high doses of CoQ10 (1200 mg per day) demonstrated symptomatic benefits in patients with early PD.[1] The putative neuroprotective activity of CoQ10 may be due to its antioxidant properties and enhancement of the mitochondrial complex I activity (which may be defective in PD). Of note, the CoQ10 product used in the study also contained significant amounts of vitamin E, another known antioxidant. The possible influence of vitamin E on the results of this study was not evaluated. However, in a previous clinical study (DATATOP), high-dose vitamin E (up to 2000 IU per day) was not associated with clinical symptomatic or neuroprotective benefits.[2]

Dopamine Agonists

Although dopamine agonists have been used to provide symptomatic relief in PD for many years, attention is now focused on putative neuroprotective effects of these agents. In vivo experiments have demonstrated that the ergot (eg, bromocriptine, pergolide) and nonergot (eg, pramipexole, ropinirole) dopamine agonists protect cultured cells from death due to oxidative damage. Recently published clinical data in patients with early PD provide intriguing neuroimaging results suggesting a putative neuroprotective effect.

The Parkinson Study Group used single-photon emission computed tomography (SPECT) to compare the effects of pramipexole vs levodopa on PD progression. The imaging ligand [123I] beta-CIT was used as a marker of dopamine transporter density. Results of the 46-month study demonstrated that pramipexole-treated patients had reduced loss of striatal dopamine uptake compared with levodopa-treated patients.[3] The Requip as Early Therapy versus L-dopa PET (REAL-PET) study used serial positron emission tomography (PET) scans to assess PD progression in patients receiving ropinirole vs levodopa.[4] The ligand 18F-dopa was used as a marker of the functional integrity of dopamine terminals. After 2 years, ropinirole-treated patients demonstrated a significantly slower loss of putamen dopamine storage capacity compared with levodopa-treated patients. It is important to note that neither study contained a placebo arm.

Therefore, it is unknown whether the dopamine agonist was acting as a neuroprotectant and slowing the rate of neuronal loss or whether levodopa was increasing the rate of neuronal loss. Additionally, the variable sensitivity of functional imaging data to clinical changes and the effects of dopamine agonists on altering dopamine transporters and receptors have made the neuroimaging data difficult to interpret in terms of neuroprotection. Therefore, definitive neuroprotection cannot be confirmed on the basis of these studies.


Rasagiline is a selective monoamine oxidase type B inhibitor that has demonstrated antioxidant and antiapoptotic activity in preclinical experimental models. Clinically, rasagiline has demonstrated symptomatic benefits in patients with early and advanced PD. In the 26-week, randomized, placebo-controlled TEMPO study, patients with early PD benefitted from rasagiline treatment.[5] However, the study was not designed to detect neuroprotective benefits. Rasagiline is anticipated to be available in the United States in late 2004.

Post a Comment

Featured Products From the ProHealth Store
Energy NADH™ 12.5mg Optimized Curcumin Longvida® Vitamin D3 Extreme™

Article Comments

Be the first to comment on this article!

Post a Comment

Optimized Curcumin Longvida with Omega-3

Featured Products

Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength

Natural Remedies

Magnesium + Malic Acid: One-Two Punch for Pain & Fatigue Magnesium + Malic Acid: One-Two Punch for Pain & Fatigue
Eating Fat is Good... Maybe... Could Be... Sometimes Eating Fat is Good... Maybe... Could Be... Sometimes
How Glutathione Can Save Your Life How Glutathione Can Save Your Life
Carry a Massage Therapist in Your Pocket Carry a Massage Therapist in Your Pocket
Front Line Defense Against Colds & Flu - Support for Healthy Immune System Balance Front Line Defense Against Colds & Flu - Support for Healthy Immune System Balance

ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
Credit Card Processing
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map